Owned by investment fund Naxicap Partners since 2019, Moria specializes in the design and manufacture of ophthalmic microsurgery instruments and equipment for refractive surgery and corneal transplant surgery.
Advised by Potomac Transactions, Moria made the landmark acquisition of the Italian company Alchimia. Based in Padua, Alchimia designs and manufactures pharmaceutical products for ophthalmic surgery (ophthalmic gels, anterior & posterior segment dyes, ophthalmic gases, perfluorocarbons, and silicone oils) and for human tissues (eye bank).
This strategic acquisition allows Moria to diversify into the high-growth ophthalmic pharmaceuticals market and to leverage strong commercial synergies, particularly in the US where Alchimia historically operates with unique products.
As advisor to the company since 2019, Potomac Transactions once again demonstrated its ability to lead and execute international acquisitions. Our industry expertise and in-depth knowledge of the Italian market enabled us to successfully complete this acquisition of over €30 million – a primary investment.
With more than €6 billion under management, Naxicap Partners has established itself as a leading European fund. Naxicap Partners contributes to the development of its portfolio companies with an approach that combines operational, strategic and financial expertise to accelerate their development in France and abroad.